DiGA in Germany: Achievable Prices After Price Negotiation or a Decision of the Arbitration Board
Author(s)
Meyer-Harms R1, Koppenhöfer S1, Pütz DC2
1Ecker + Ecker GmbH, Hamburg, SH, Germany, 2Ecker + Ecker GmbH, Hamburg, Germany
OBJECTIVES: In Germany, people insured with the statutory health insurance are entitled to treatment with digital health applications (DiGA). The reimbursement prices of DiGA are negotiated with the National Association of Health Insurance Funds (GKV-SV) or decided by the arbitration board if the negotiation fails. Here, we surveyed the prices of DiGA after price negotiation or arbitral award and analyzed whether differences of prices can be explained by positive health care effect, indication or whether the price was negotiated or determined by an arbitral award.
METHODS: The DiGA directory of the BfArM and arbitral awards were screened. Selected DiGA were grouped by indication, positive healthcare effect and whether the price resulted from a successful negotiation or was set by an arbitral award. Then price levels of these groups were compared.
RESULTS: Currently (June 2023), reimbursement prices for 14 DiGA are available, 7 of which were decided by the arbitration board. Out of these 14 DiGA, 10 are indicated for physiological diseases and one each for a neurological disorder, a muscular disorder, a metabolic disease, and tinnitus.
The manufacturer's price for these DiGA varies between 204 € and 744 € and averages at 491 €, while the reimbursement price varies between 189 € and 243 € and averages at 221 €. The average reimbursement price determined by the arbitration board is 218 €. There was no detectable correlation of the prices with any of the factors defined.CONCLUSIONS: Negotiated prices did not differ significantly from those determined by the arbitration board. Similarly, indication and positive health care had no influence on the reimbursement price. However, most available prices are for DiGA in psychological indications and implement some kind of psychotherapy. Although the price corridor for DiGA seems fixed and rather narrow, how new indications and innovative therapeutic approaches influence attainable prices remains to be seen.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
HPR40
Topic
Health Policy & Regulatory, Medical Technologies
Topic Subcategory
Insurance Systems & National Health Care, Pricing Policy & Schemes, Reimbursement & Access Policy
Disease
No Additional Disease & Conditions/Specialized Treatment Areas